文献速递肝病

非酒精性脂肪性肝炎药物治疗试验中安慰剂应答率及相关因素:系统综述与Meta分析

Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-06-18

该系统综述与Meta分析纳入39项随机对照试验、1463例接受安慰剂的非酒精性脂肪性肝炎(NASH)成人患者,评估组织学和/或磁共振影像指标。结果显示25%安慰剂组患者NAS改善≥2分(95%CI 21%-29%),肝脂肪变、气球样变、小叶炎症和纤维化评分改善率分别为33%±3%、30%±3%、32%±3%和21%±3%,提示设计NASH药物试验时应考虑安慰剂应答。

要点

  • 安慰剂组25%患者NAS改善≥2分(95%CI 21%-29%),异质性I²=27%。
  • 安慰剂组肝脂肪变、气球样变、小叶炎症、纤维化评分改善≥1分者分别约33%、30%、32%、21%。
  • 基线NAS较高、南美开展及BMI下降的试验与安慰剂组NAS改善更大相关。

核心结论

  • 在NASH随机对照试验的Meta分析中,接受安慰剂的患者有显著的组织学、影像学和生化应答。
  • 设计NASH治疗药物试验时应考虑安慰剂应答。

研究设计与样本

  • 系统综述与Meta分析,纳入39项随机对照试验中接受安慰剂的1463例NASH成人患者。
  • 通过检索MEDLINE、EMBASE、Cochrane Central Register of Controlled Trials和Scopus(各库建库至2018年1月2日)识别试验。
  • 组织学评估数据来自956例患者,磁共振波谱数据来自295例患者,磁共振质子密度脂肪分数测量数据来自61例患者。

主要发现

  • 25%接受安慰剂的患者NAS改善≥2分(95%CI 21%-29%),异质性较小(I²=27%)。
  • 肝脂肪变评分改善≥1分者33%±3%,肝细胞气球样变评分改善≥1分者30%±3%,小叶炎症评分改善≥1分者32%±3%,纤维化评分改善≥1分者21%±3%,试验间异质性中等(I²范围51%-63%)。
  • 接受安慰剂的患者NAS改善0.72±0.19,异质性大(I²=96%)。
  • 单变量和多变量Meta回归显示,基线NAS较高的试验、在南美开展的试验以及患者BMI下降的试验,与安慰剂组NAS改善更大相关。
  • 接受安慰剂的患者肝内甘油三酯(磁共振波谱测量)显著降低1.45%±0.54%,异质性中等(I²=40%);磁共振质子密度脂肪分数显著降低2.43±0.89,无异质性(I²=0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is important to know the extent of the placebo effect in designing randomized controlled trials for patients with nonalcoholic steatohepatitis (NASH), to accurately calculate sample size and define treatment endpoints. METHODS: We performed a systematic review and meta-analysis of the placebo groups from randomized controlled trials of adults with NASH that provided histologic and/or magnetic resonance image-based assessments. We identified trials through a comprehensive search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus, from each database's inception through January 2, 2018. RESULTS: We identified 39 randomized controlled trials, comprising 1463 patients who received placebo. Histologic assessment data (the nonalcoholic fatty liver disease activity scores, NAS) were available from 956 patients; magnetic resonance spectroscopy data were available from 295 patients and magnetic resonance proton density fat fraction measurements from 61 patients. Overall, 25% of patients given placebo had an improvement in NAS by 2 or more points (95% CI, 21%-29%) with a small amount of heterogeneity (I2 = 27%). There were improvements by at least 1 point in steatosis scores of 33% ± 3% of patients, in hepatocyte ballooning scores of 30% ± 3% of patients, in lobular inflammation scores of 32% ± 3% of patients, and in fibrosis scores of 21% ± 3% of patients, with a moderate amount of heterogeneity among trials (I2 range, 51%-63%). Patients given placebo had a statistically significant improvement in NAS (by 0.72 ± 0.19), with a large amount of heterogeneity (I2 = 96%). Univariate and multivariate meta-regression showed that trials with a higher baseline NAS, those conducted in South America, and those in which patients had a decrease in body mass index, were associated with greater improvements in NAS among patients given placebo. Patients given placebo had significant reductions in intrahepatic triglyceride, measured by magnetic resonance spectroscopy (by 1.45% ± 0.54%) with moderate heterogeneity (I2 = 40%), and in magnetic resonance proton density fat fraction (by 2.43 ± 0.89), without heterogeneity (I2 = 0). Mean serum levels of alanine and aspartate aminotransferases decreased significantly (by 11.7 ± 3.8 U/L and 5.9 ± 2.1 U/L, respectively; P < .01 for both). CONCLUSIONS: In a meta-analysis of randomized controlled trials of NASH, patients given placebo have significant histologic, radiologic, and biochemical responses. The placebo response should be considered in designing trials of agents for treatment of NASH.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Han MAT, Altayar O, Hamdeh S, et al. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018. PMID: 29913275. doi:10.1016/j.cgh.2018.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。